International Clinical Pharmacogenomics Training Symposium – in Collaboration with Colorado University

This interactive, practice-based program will teach healthcare professionals and students the fundamentals of pharmacogenomics and how to use this information to improve patient care through addressing competencies outlined by the Genetics and Genomics Competency Center (G2C2) and the American Society of Health-System Pharmacists (ASHP). 

The course duration is 5-days. Topics covered include: Fundamentals of Pharmacogenomics; Advanced Concepts in Pharmacogenomics; Pharmacogenomic Laboratory Methods; Genetics and Clinical Pharmacology; Genotyping Tests and Interpretation; Pharmacogenomic Evidence, Study Designs, and Guidelines; Case-based scenarios of clinically-actionable pharmacogenomic examples in the areas of Cardiology, Drug Hypersensitivity Reactions, Psychiatry and Neurology, Pain Management, specific drugs (Voriconazole, Ondansetron, Tacrolimus) and oncology.

The program goal is to provide healthcare professionals with an understanding of how genetic factors influence drug disposition, response, and adverse effects. Knowledge gained from this program will enhance a participant’s ability to apply pharmacogenomic information to clinical practice and select the most appropriate therapeutic interventions.

Upon completion of this course, participants will be able to:

• Demonstrate an understanding of fundamental pharmacogenomics concepts and nomenclature.
• Demonstrate an understanding of how genetic variation contributes to inter-individual variability in drug pharmacokinetics, pharmacodynamics, and adverse effects.
• Obtain pharmacogenomics information via popular web-based resources (e.g., PharmGKB).
• Recommend pharmacogenomics testing, when appropriate, to aid in drug and dose selection.
• Evaluate the results of pharmacogenomics tests and apply the results to patient care.
• Critically evaluate the pharmacogenomics literature, including genome-wide association studies.
• Use evidence-based guidelines to formulate patient-specific medication plans based on pharmacogenomics test results and other patient factors.
• Communicate pharmacogenomics-specific medication recommendations to the health care team.
• Educate health care professionals and patients about the indications for and clinical utility of pharmacogenomics testing.
• Educate health care professionals and patients about the ethical, legal, social, and economic implications of pharmacogenomics testing.
• Identify the key elements of pharmacogenomics implementation and formulate a clinical pharmacogenomics implementation plan.

To be announce